Leadiant Biosciences (formerly Sigma-Tau) is an Italian rare-disease company that holds the US application for procarbazine (Matulane).
Leadiant Biosciences, based in Rome and formerly Sigma-Tau, is an Italian rare disease company that holds the US application for procarbazine, sold as Matulane. It markets niche and rare disease products including Matulane for Hodgkin lymphoma, as well as pegademase and cysteamine formulations. OnCo links it to the procarbazine drug record. Whether an old drug held by a small company remains reliably available and affordable is the question that matters for the regimens that still use it. Procarbazine has its own page.
Procarbazine (Matulane) is an old chemotherapy capsule from the MOPP regimen for Hodgkin lymphoma; it is now used mainly in the PCV combination for certain brain tumours.
Shares Procarbazine, Hodgkin lymphoma.
Shares Procarbazine, Hodgkin lymphoma.
Shares Procarbazine, Hodgkin lymphoma.
Shares Procarbazine, Hodgkin lymphoma.
Shares Procarbazine, Hodgkin lymphoma.
Shares Procarbazine, Hodgkin lymphoma.
Shares Procarbazine, Hodgkin lymphoma.
Shares Procarbazine, Hodgkin lymphoma.